Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells
Zhuo-Xun Wu1, Qiu-Xu Teng1, Chao-Yun Cai1
1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.
Abstract:
Overexpression of ABCB1 transporters plays a crucial role in mediating multidrug resistance (MDR). Therefore, it is important to inhibit ABCB1 activity in order to maintain an effective intracellular level of chemotherapeutic drugs. Tepotinib is a MET tyrosine kinase inhibitor with potential anticancer effect and it is currently in clinical trials. In this study, we investigated whether tepotinib could antagonize ABC transporters-mediated MDR. Our results suggest that tepotinib significantly reversed ABCB1-mediated MDR but not ABCG2- or ABCC1-mediated MDR. Mechanistic studies show that tepotinib significantly reversed ABCB1-mediated MDR by attenuating the efflux activity of ABCB1 transporter. The ATPase assay showed that tepotinib inhibited the ATPase activity of ABCB1 in a concentration-dependent manner. Furthermore, treatment with tepotinib did not change protein expression or subcellular localization of ABCB1. Docking analysis indicated that tepotinib interacted with the drug-binding site of the ABCB1 transporter. Our study provides a potential chemotherapeutic strategy of co-administrating tepotinib with other conventional chemotherapeutic agents to overcome MDR and improve therapeutic effect.
Insights
Tepotinib effectively reverses multidrug resistance (MDR) mediated by ABCB1 transporters by inhibiting their efflux activity. This suggests tepotinib as a potential co-treatment to enhance chemotherapy effectiveness.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Multidrug resistance (MDR) mediated by ABCB1 transporters limits chemotherapy efficacy.
- Inhibiting ABCB1 is crucial for maintaining effective intracellular drug concentrations.
Purpose of the Study:
- To investigate tepotinib's potential to antagonize ABC transporter-mediated MDR.
- To elucidate the mechanisms by which tepotinib affects ABCB1 activity.
Main Methods:
- Cell-based assays to assess MDR reversal.
- ATPase assays to measure transporter activity.
- Western blotting and subcellular localization studies.
- Molecular docking analysis.
Main Results:
- Tepotinib significantly reversed ABCB1-mediated MDR, but not MDR mediated by ABCG2 or ABCC1.
- Tepotinib inhibited ABCB1 efflux activity and ATPase activity in a concentration-dependent manner.
- Protein expression and subcellular localization of ABCB1 remained unchanged.
- Docking analysis suggested tepotinib binds to the ABCB1 drug-binding site.
Conclusions:
- Tepotinib antagonizes ABCB1 transporter activity, offering a strategy to overcome MDR.
- Co-administration of tepotinib with chemotherapeutics may improve treatment outcomes in cancer patients.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Receptor-mediated Endocytosis
Diode: Reverse bias
Reversible and Irreversible Processes


